Filter by country
Africa
Sao Tome and Principe
Liberia
Madagascar
Malawi
Mali
Mauritania
Mozambique
Niger
Nigeria
Rwanda
Lesotho
Senegal
Sierra Leone
South Sudan
Tanzania, UR
Togo
Uganda
Zambia
Zimbabwe
Cote d'Ivoire
Benin
Burkina Faso
Burundi
Cameroon
Central African Republic (the)
Chad
Comoros (the)
Congo (the)
Angola
Congo, DR
Eritrea
Ethiopia
The Gambia
Ghana
Guinea-Bissau
Guinea
Kenya
South-East Asia
Bangladesh
Bhutan
China
Korea, DPR
India
Indonesia
Myanmar
Nepal
Sri Lanka
Timor Leste
Americas
Cuba
Haiti
Honduras
Nicaragua
Bolivia
Guyana
Europe
Albania
Armenia
Azerbaijan
Bosnia-Herzegovina
Georgia
Kyrgyzstan
Moldova
Tajikistan
Turkmenistan
Ukraine
Uzbekistan
Western Pacific
Cambodia
Kiribati
Lao PDR
Mongolia
Papua New Guinea
Solomon Islands
Vietnam
Eastern Mediterranean
Afghanistan
Djibouti
Pakistan
Somalia
Sudan (the)
Yemen
Filter by Category
Documents
Gavi Process Guidelines
IRC reports
Portuguese
Annual Contributions and Proceeds
Cash Receipts
Advocacy
Resource mobilisation
German
COVID-19 situation report
COVAX documents
COVAX AMC
Russian
Gavi Programme Funding Guidelines
Programme audit
Internal audit
Investigation
Reports to the Board
Other (IA)
COVAX data brief
DHI
VIS
White papers
AMC Documents
Country Documents
Evaluations
Financial Reports
Guidelines and Forms
Legal
Strategy
Supply and Procurement
Policies
Annual Reports
Gavi Fact Sheets
Gavi Publications
The Evidence Base
Gavi Bulletin
Other Publishers
Board Minutes
Committee minutes
Audit
Spanish
News
AMC Updates
Gavi Features
Press Releases
Roi
Statements
Gavi Blogs
Vaccineswork
Theme - Pentavalent
Top stories
3rd donor pledging
3rd donor pledging featured
Partner news
IATI
Social media toolkit
Audio Visual
Infographics
Presentations
Videos
Galleries
Board
Committee
Members

Articles (4215)

Showing 12 of 4215 View All
Showing 216 of 352 pages

Globalizing the COVID Vaccine

In less than a year, the world has come together to develop effective COVID-19 vaccines and a multilateral platform for allocating them most efficiently around the world. But with the risk of vaccine nationalism still looming large, now is the…

What do the new COVID-19 variants mean for vaccine development?

Viruses are constantly mutating and often this process does not have any impact on the risk they pose to humans. However, occasionally mutations can occur which make it easier for viruses to infect us, or which could render vaccines against them…

Long COVID: who is at risk?

Long-lasting symptoms appear unrelated to how bad your infection was, though women appear more affected than men.

What you need to know about a COVID-19 vaccine

Answers to the most common questions about coronavirus vaccine development.

Managing Well in the Work-From-Home Era

Managers owe it to their employees to stop treating work from home like a luxury. The office wasn’t invited into the home. It turned up like an unexpected guest – and it shows few signs of leaving soon.

What are whole virus vaccines and how could they be used against COVID-19?

Whole virus vaccines use a weakened or deactivated version of the disease-causing virus to trigger protective immunity against it.

Seven vital questions about RNA Covid-19 vaccines

The Pfizer-BioNTech and Moderna Covid-19 vaccines are more than 90% effective, as reported in phase III clinical trials – and the Pfizer-BioNTech vaccine is the first Covid-19 vaccine to be licensed.

What are viral vector-based vaccines and how could they be used against COVID-19?

Viral vector-based vaccines use a harmless virus to smuggle the instructions for making antigens from the disease-causing virus into cells, triggering protective immunity against it.

How close are we to a ‘workable’ HIV vaccine?

Despite huge advancements in the treatment and prevention of HIV/AIDS in recent decades, an effective vaccine remains elusive – and is desperately needed to end the global pandemic that kills more than 700,000 people each year.

Severe COVID may be caused by 'autoantibodies' – here is what that means

Antibodies that go rogue and attack healthy tissue identified in patients with severe COVID.

Gavi welcomes final approval of U.S. support for global immunisation in Year-End Omnibus and COVID Supplemental Package

The United States has approved US$ 4 billion for Gavi, the Vaccine Alliance to ensure lower-income economies have equitable access to safe and effective COVID-19 vaccines on the same urgent timeline as wealthier countries.

What are protein subunit vaccines and how could they be used against COVID-19?

Protein subunit vaccines use fragments of protein from the disease-causing virus to trigger protective immunity against it.

Subscribe to our newsletter